IL324854A - טיפול בסוכרת מסוג 1 (t1d) עם ננו-חלקיקים עמידים - Google Patents

טיפול בסוכרת מסוג 1 (t1d) עם ננו-חלקיקים עמידים

Info

Publication number
IL324854A
IL324854A IL324854A IL32485425A IL324854A IL 324854 A IL324854 A IL 324854A IL 324854 A IL324854 A IL 324854A IL 32485425 A IL32485425 A IL 32485425A IL 324854 A IL324854 A IL 324854A
Authority
IL
Israel
Prior art keywords
timp
subject
various embodiments
cells
administering
Prior art date
Application number
IL324854A
Other languages
English (en)
Original Assignee
Cour Pharmaceuticals Dev Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cour Pharmaceuticals Dev Company Inc filed Critical Cour Pharmaceuticals Dev Company Inc
Publication of IL324854A publication Critical patent/IL324854A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL324854A 2023-05-25 2024-05-24 טיפול בסוכרת מסוג 1 (t1d) עם ננו-חלקיקים עמידים IL324854A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363504271P 2023-05-25 2023-05-25
US202463566571P 2024-03-18 2024-03-18
PCT/US2024/031020 WO2024243524A1 (en) 2023-05-25 2024-05-24 Treatment of type 1 diabetes (t1d) with tolerizing nanoparticles

Publications (1)

Publication Number Publication Date
IL324854A true IL324854A (he) 2026-01-01

Family

ID=91586101

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324854A IL324854A (he) 2023-05-25 2024-05-24 טיפול בסוכרת מסוג 1 (t1d) עם ננו-חלקיקים עמידים

Country Status (8)

Country Link
EP (1) EP4719464A1 (he)
KR (1) KR20260018860A (he)
CN (1) CN121398841A (he)
AU (1) AU2024277573A1 (he)
IL (1) IL324854A (he)
MX (1) MX2025013754A (he)
TW (1) TW202500576A (he)
WO (1) WO2024243524A1 (he)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
JP7194593B2 (ja) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
EP3400069A4 (en) 2016-01-04 2019-09-25 Cour Pharmaceuticals Development Company Inc. Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes
WO2019151939A1 (en) * 2018-02-05 2019-08-08 Diamyd Medical Ab Novel composition and use thereof

Also Published As

Publication number Publication date
CN121398841A (zh) 2026-01-23
TW202500576A (zh) 2025-01-01
WO2024243524A1 (en) 2024-11-28
KR20260018860A (ko) 2026-02-09
EP4719464A1 (en) 2026-04-08
MX2025013754A (es) 2026-02-03
AU2024277573A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
US20240408186A1 (en) Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles
KR20250004784A (ko) 치료용 벡터 및 단백질의 면역원성을 극복하기 위한 관용화 면역 변형 나노입자
US20240201187A1 (en) Method of Tracking Maintenance of Immunological Tolerance
IL324854A (he) טיפול בסוכרת מסוג 1 (t1d) עם ננו-חלקיקים עמידים
US20240197866A1 (en) Treatment of peanut allergy with tolerizing nanoparticles
JP2026511042A (ja) 重症筋無力症の治療のための寛容化免疫修飾ナノ粒子
EP4604999A1 (en) Treatment of peanut allergy with tolerizing nanoparticles
WO2026019942A2 (en) Tolerizing immune modifying nanoparticles for treatment of narcolepsy
TW202610681A (zh) 用於治療猝睡症之耐受性免疫修飾奈米粒子
WO2026015713A1 (en) Tolerizing immune modifying nanoparticles for treatment of alpha gal syndrome
EA051125B1 (ru) Лечение первичного билиарного холангита (pbc) толерогенными наночастицами
CN118510546A (zh) 利用耐受性纳米颗粒治疗原发性胆汁性胆管炎（pbc）
EP4482588A2 (en) Treatment of solid tumors with negatively charged particles